Breakthrough T1D & NIH Workshop at the Intersection of Immunology and Bioengineering
Breakthrough T1D and NIH bring together top scientists and engineers to strategize on how to allow implanted beta cells to…
Abbott FreeStyle Libre 2 iOS App Receives FDA Approval
On August 2, 2021, Abbott announced the FreeStyle Libre 2 iOS app received approval from the FDA for adults and…
FDA Approves Semglee® as the First Interchangeable Biosimilar Insulin Product
The U.S. Food and Drug Administration (FDA) approved Semglee® (insulin glargine-yfgn) as the first ever interchangeable biosimilar insulin product. Semglee®…
Two Studies Shed Light on Diabetic Kidney Disease
Two recent publications shed light on which people with type 1 diabetes will develop end-stage kidney disease, a complication of…
Eli Lilly Acquires Breakthrough T1D T1D Fund Portfolio Company Protomer Technologies
Breakthrough T1D is excited to announce that the T1D Fund portfolio company Protomer Technologies, who is developing "smart" insulin, has been acquired by Eli…
Teplizumab (the Therapy that Delays T1D By Nearly 3 Years) Isn’t Approved…Yet
The FDA issued a letter to Provention Bio for the use of teplizumab to delay T1D in at-risk individuals, meaning…
At ADA, Breakthrough T1D-Funded Research Takes Center Stage
There were a number of fantastic results at the ADA’s Scientific Sessions. Here is a video and a summary of…
Video: ADA’s Scientific Sessions: Day 4
Here is Dr. Camillo Ricordi to share his key takeaways from day 4 from the American Diabetes Association's Scientific Sessions.
ADA’s Scientific Sessions: Day 3
Here are Drs. Jennifer Sun, Dana Lewis, and Christine Wang to share their key takeaways from day 3, with their…
ADA’s Scientific Sessions: Day 2
Drs. Danny Chou, Peter Arvan, Jeffrey Millman, and Efsun Arda will share their key takeaways from day 2, with their…
